

Oncology Today with Dr Neil Love: Novel Immunotherapeutic Strategies in Melanoma

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following best describes the mechanism of action of lenvatinib, a drug being tested in combination with pembrolizumab for the treatment of patients with advanced melanoma who had disease progression on anti-PD-(L)1 therapy?
 - a. VEGF inhibitor
 - b. TIM-3 inhibitor
 - c. CTLA-4 inhibitor
 - d. LAG-3 inhibitor
2. Which of the following results have been reported for the combination of relatlimab and nivolumab versus nivolumab alone in patients receiving treatment for first-line advanced melanoma in the phase III RELATIVITY-047 trial?
 - a. There was no progression-free survival (PFS) benefit observed in patients who received the combination of relatlimab and nivolumab, regardless of their tumor's LAG-3 expression
 - b. Patients whose tumors had LAG-3 expression $\geq 1\%$ had a PFS benefit from relatlimab plus nivolumab
 - c. There was a PFS benefit observed in all patients who received relatlimab plus nivolumab, regardless of their tumor's LAG-3 expression
3. Which of the following results have been reported for the combination of lenvatinib plus pembrolizumab in the Phase II LEAP-004 trial of patients with unresectable stage III or IV melanoma who progressed on anti-PD-(L)1 therapy?
 - a. Six-month duration of response was less than 60%
 - b. Objective response rate (ORR) was about 20%
 - c. Median progression-free survival was longer than 7 months
 - d. Median overall survival was about 10 months
4. Which of the following was the most common grade 3/4 adverse event in patients receiving lenvatinib plus pembrolizumab in the Phase II LEAP-004 trial?
 - a. Hypothyroidism
 - b. Nausea
 - c. Diarrhea
 - d. Hypertension